' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8.8
USERS' SCORE
Good
Based on 88 Reviews
8.9
Supplement Facts
Serving Size: 1 Veggie Capsule
Amount Per Serving
%DV
Nattokinase (from fibrinase enzymes)
2,000 FU**
†
Top Medical Research Studies
9.5
Nattokinase shows promise for hearts
Exploring the In Vitro Thrombolytic Activity of Nattokinase From a New Strain Pseudomonas aeruginosa CMSS.
Directly targets heart attack therapy
We aimed to explore the effectiveness of nattokinase, an enzyme with potent fibrinolytic properties, in treating heart attacks. Through our research, we focused on enhancing the production of nattokinase from a newly identified strain of Pseudomonas aeruginosa, referred to as CMSS, which we isolated from cow milk.
Our comprehensive study involved optimizing different growth conditions such as pH, temperature, and nutrient sources, alongside improving the strain through UV-mutagenesis. We were excited to find that these optimizations led to a significant increase in nattokinase production.
The standout results showed that our modified strain produced nattokinase with a maximum activity of 4263 U mL(-1), which is double that of the original strain. In practical terms, this nattokinase achieved an impressive 94% blood clot lysis within ten minutes, hinting at its potential as a rapid acting treatment for heart-related issues.
Overall, our findings suggest that nattokinase from Pseudomonas aeruginosa CMSS could be a promising candidate for thrombolytic therapy, notably for those at risk of acute myocardial infarction. This unique study represents the first report of nattokinase production from this microorganism, opening the door to further research.
Our comprehensive study involved optimizing different growth conditions such as pH, temperature, and nutrient sources, alongside improving the strain through UV-mutagenesis. We were excited to find that these optimizations led to a significant increase in nattokinase production.
The standout results showed that our modified strain produced nattokinase with a maximum activity of 4263 U mL(-1), which is double that of the original strain. In practical terms, this nattokinase achieved an impressive 94% blood clot lysis within ten minutes, hinting at its potential as a rapid acting treatment for heart-related issues.
Overall, our findings suggest that nattokinase from Pseudomonas aeruginosa CMSS could be a promising candidate for thrombolytic therapy, notably for those at risk of acute myocardial infarction. This unique study represents the first report of nattokinase production from this microorganism, opening the door to further research.
Read More
8
Nattokinase nanozyme aids heart recovery
A Nattokinase-Loaded Nanozyme for Alleviating Acute Myocardial Infarction via Thrombolysis and Antioxidation.
Study highlights nattokinase’s heart benefits
We designed a study to explore the effectiveness of nattokinase in treating acute myocardial infarction, a condition often caused by blood clots. Thrombus formation leads to reduced blood flow, and finding effective treatments is critical for improving outcomes in heart attack patients.
Nattokinase is a naturally occurring enzyme known for its ability to dissolve blood clots, but its clinical use has been limited due to stability issues. To overcome this, we developed a manganese oxide nanozyme loaded with nattokinase, called MnOx@NK. This innovative approach not only delivers the clot-busting properties of nattokinase but also provides antioxidant benefits.
In our experiments using a mouse model of heart attack, we administered MnOx@NK through tail vein injections. The results were promising: we observed significant improvements in vascular function and a notable reduction in myocardial injury. The nanozyme effectively protected against oxidative stress, which can worsen the damage caused by heart attacks.
Overall, our findings suggest that using nattokinase-loaded nanozymes may pave the way for new treatments for acute myocardial infarction, potentially offering a safer and more effective option for patients facing this severe condition.
Nattokinase is a naturally occurring enzyme known for its ability to dissolve blood clots, but its clinical use has been limited due to stability issues. To overcome this, we developed a manganese oxide nanozyme loaded with nattokinase, called MnOx@NK. This innovative approach not only delivers the clot-busting properties of nattokinase but also provides antioxidant benefits.
In our experiments using a mouse model of heart attack, we administered MnOx@NK through tail vein injections. The results were promising: we observed significant improvements in vascular function and a notable reduction in myocardial injury. The nanozyme effectively protected against oxidative stress, which can worsen the damage caused by heart attacks.
Overall, our findings suggest that using nattokinase-loaded nanozymes may pave the way for new treatments for acute myocardial infarction, potentially offering a safer and more effective option for patients facing this severe condition.
Read More
Most Useful Reviews
9.5
No further heart attacks
I learned about nattokinase after my father was diagnosed with heart problems, having suffered a heart attack. We consulted his physician and switched to natural treatment with nattokinase. After a year, his blood circulation improved, and he hasn't had any further heart attacks. This truly is essential for heart patients.
Read More
9.5
Combats heart issues
This unique enzyme is crucial for preventing numerous diseases, particularly those related to the heart. It dissolves excess fibrin in blood vessels, improves circulation, and lowers the risk of heart attacks. I personally experienced relief from severe symptoms after taking nattokinase, alongside serrapeptase and arjuna.
Read More
9.5
No arrhythmia recurrence
This superb drug has supported me for two years following a heart failure and arrhythmia. Switching from Xarelto to nattokinase has been incredibly beneficial, as there have been no arrhythmia recurrences since then.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8.8
9.5
Nattokinase shows promise for hearts
Exploring the In Vitro Thrombolytic Activity of Nattokinase From a New Strain Pseudomonas aeruginosa CMSS.
Directly targets heart attack therapy
We aimed to explore the effectiveness of nattokinase, an enzyme with potent fibrinolytic properties, in treating heart attacks. Through our research, we focused on enhancing the production of nattokinase from a newly identified strain of Pseudomonas aeruginosa, referred to as CMSS, which we isolated from cow milk.
Our comprehensive study involved optimizing different growth conditions such as pH, temperature, and nutrient sources, alongside improving the strain through UV-mutagenesis. We were excited to find that these optimizations led to a significant increase in nattokinase production.
The standout results showed that our modified strain produced nattokinase with a maximum activity of 4263 U mL(-1), which is double that of the original strain. In practical terms, this nattokinase achieved an impressive 94% blood clot lysis within ten minutes, hinting at its potential as a rapid acting treatment for heart-related issues.
Overall, our findings suggest that nattokinase from Pseudomonas aeruginosa CMSS could be a promising candidate for thrombolytic therapy, notably for those at risk of acute myocardial infarction. This unique study represents the first report of nattokinase production from this microorganism, opening the door to further research.
Our comprehensive study involved optimizing different growth conditions such as pH, temperature, and nutrient sources, alongside improving the strain through UV-mutagenesis. We were excited to find that these optimizations led to a significant increase in nattokinase production.
The standout results showed that our modified strain produced nattokinase with a maximum activity of 4263 U mL(-1), which is double that of the original strain. In practical terms, this nattokinase achieved an impressive 94% blood clot lysis within ten minutes, hinting at its potential as a rapid acting treatment for heart-related issues.
Overall, our findings suggest that nattokinase from Pseudomonas aeruginosa CMSS could be a promising candidate for thrombolytic therapy, notably for those at risk of acute myocardial infarction. This unique study represents the first report of nattokinase production from this microorganism, opening the door to further research.
Read More
8
Nattokinase nanozyme aids heart recovery
A Nattokinase-Loaded Nanozyme for Alleviating Acute Myocardial Infarction via Thrombolysis and Antioxidation.
Study highlights nattokinase’s heart benefits
We designed a study to explore the effectiveness of nattokinase in treating acute myocardial infarction, a condition often caused by blood clots. Thrombus formation leads to reduced blood flow, and finding effective treatments is critical for improving outcomes in heart attack patients.
Nattokinase is a naturally occurring enzyme known for its ability to dissolve blood clots, but its clinical use has been limited due to stability issues. To overcome this, we developed a manganese oxide nanozyme loaded with nattokinase, called MnOx@NK. This innovative approach not only delivers the clot-busting properties of nattokinase but also provides antioxidant benefits.
In our experiments using a mouse model of heart attack, we administered MnOx@NK through tail vein injections. The results were promising: we observed significant improvements in vascular function and a notable reduction in myocardial injury. The nanozyme effectively protected against oxidative stress, which can worsen the damage caused by heart attacks.
Overall, our findings suggest that using nattokinase-loaded nanozymes may pave the way for new treatments for acute myocardial infarction, potentially offering a safer and more effective option for patients facing this severe condition.
Nattokinase is a naturally occurring enzyme known for its ability to dissolve blood clots, but its clinical use has been limited due to stability issues. To overcome this, we developed a manganese oxide nanozyme loaded with nattokinase, called MnOx@NK. This innovative approach not only delivers the clot-busting properties of nattokinase but also provides antioxidant benefits.
In our experiments using a mouse model of heart attack, we administered MnOx@NK through tail vein injections. The results were promising: we observed significant improvements in vascular function and a notable reduction in myocardial injury. The nanozyme effectively protected against oxidative stress, which can worsen the damage caused by heart attacks.
Overall, our findings suggest that using nattokinase-loaded nanozymes may pave the way for new treatments for acute myocardial infarction, potentially offering a safer and more effective option for patients facing this severe condition.
Read More
User Reviews
USERS' SCORE
Good
Based on 88 Reviews
8.9
9.5
No further heart attacks
I learned about nattokinase after my father was diagnosed with heart problems, having suffered a heart attack. We consulted his physician and switched to natural treatment with nattokinase. After a year, his blood circulation improved, and he hasn't had any further heart attacks. This truly is essential for heart patients.
Read More
9.5
Combats heart issues
This unique enzyme is crucial for preventing numerous diseases, particularly those related to the heart. It dissolves excess fibrin in blood vessels, improves circulation, and lowers the risk of heart attacks. I personally experienced relief from severe symptoms after taking nattokinase, alongside serrapeptase and arjuna.
Read More
9.5
No arrhythmia recurrence
This superb drug has supported me for two years following a heart failure and arrhythmia. Switching from Xarelto to nattokinase has been incredibly beneficial, as there have been no arrhythmia recurrences since then.
9.5
Blood density management
Nattokinase, widely researched in Asia, is highly valued for its blood clot-dissolving properties. It serves as an effective prevention method against heart attack and cardiovascular diseases, making it the best alternative to aspirin.
9.5
Prevents blood clots
Nattokinase is an essential enzyme that enhances blood flow and prevents blood clotting, reducing the risk of heart attacks. Those who consume natto, like many Japanese, tend to have a healthy cardiovascular system, and I find it a great alternative to aspirin for maintaining normal blood viscosity. It also helps with various conditions such as osteoporosis and supports immunity. I recommend it highly!
Read More
